The relevance of motivation in schizophrenia

Paulet, Manuel; Ciobîcă, Alin; Cojocaru, Ştefan; Popescu, Radu; Timofte, Daniel

doi:10.2298/abs140505122p

Cited by 2 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, motivation is a representation of numerous processes aimed at maintaining action. It is a complex interaction between physiological and social processes [22], which include adequate nutrition education tailored to the needs of each individual patient. When considering the use of Motivational Dialogue in a psychiatric setting, Villaume et al highlight its desirable effects on treatment adherence, and, by extension, also compliance with established dietary recommendations [50].…”

Section: Discussionmentioning

confidence: 99%

“…Negative symptoms of schizophrenia may contribute to motivational deficits, resulting in decreased involvement in various activities and reduced goal-oriented behaviors. The sense of agency, consisting of subjective control over the course of events, a sense of self-efficacy and freedom of choice, are suggested to be impaired in schizophrenia [21,22]. Therefore, it is often assumed that patients may lack the capacity to persevere, e.g., in their endeavors to alter their dietary habits.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Dietary Behaviors and Metabolic Syndrome in Schizophrenia Patients

Adamowicz¹,

Kucharska-Mazur²

2020

JCM

View full text Add to dashboard Cite

The metabolic syndrome (MS) is highly prevalent in schizophrenia patients, resulting from both pharmacotherapy and their lifestyle. To avoid its development, the analysis of patients’ eating behaviors followed by the necessary nutritional changes should become a routine element of treatment. The aim of this study is to investigate the effect of dietary habits on the course of schizophrenia and MS, cognitive performance, symptom severity, and subjective assessment of eating behaviors in schizophrenia patients. Total of 87 participants (63.2% women) aged 19 to 67 years (M = 41.67; SD = 12.87), of whom 60 met the IDF criteria for MS, completed the PANSS, the verbal fluency test, the Stroop Color-Word Test, and the digit span task, followed by a thorough nutritional interview. There were no significant differences in the dietary behaviors between investigated schizophrenia patients with and without comorbid MS. Interestingly, their eating habits compared quite favorably to those described in the literature. No associations were found between positive eating habits and other tested variables in patients with MS. They were, however, linked to lower PANSS scores in the entire sample. In addition, positive eating habits correlated with better cognitive performance and a more adequate subjective assessment of dietary habits. It would be amiss to assume that schizophrenia patients lack the ability to control their eating behaviors. Nutrition education may foster desirable dietary changes and improve the sense of agency, thus helping to reduce symptom severity and enhancing cognitive performance in this patient population.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Dietary Behaviors and Metabolic Syndrome in Schizophrenia Patients

Adamowicz¹,

Kucharska-Mazur²

2020

JCM

View full text Add to dashboard Cite

show abstract

“…Some of these interactions are not always apparent and may not be routinely flagged by drug-interaction programs. These include induction of metabolism by the polycyclic aromatic hydrocarbons in cigarette or cannabis smoke, inhibition of * email: lorenadima@yahoo.com, andre_martie@yahoo.com, claudiagavris@yahoo.com metabolism by caffeine consumption, and other variables such as age, race, and gender [3][4][5][6][7].…”

mentioning

confidence: 99%

Clozapine Efficacy, Type of Titration and Therapeutic Drug Monitoring Using Chemical Methods for Serum Level Assessment

Petric¹,

Dima²,

Ifteni³

et al. 2019

Rev. Chim.

View full text Add to dashboard Cite

Approximately 30% of patients are included in treatment-resistant schizophrenia and clozapine remains the only antipsychotic with proved superior efficacy in these cases. Currently, although clozapine is considered as the most effective pharmacological intervention for treatment-resistant schizophrenia in all national guidelines, its use is suboptimal due to doctors� concerns about tolerability and inappropriate adherence of patients to haematological monitoring required for early detection of severe neutropenia. Although treatment guidelines recommend the use of clozapine starting with a dose of 12.5-25 mg/day and gradual increase over a 2-week period until the therapeutic dose is reached, this recommendation was not derived from rigorous controlled studies. Slow or standard titration of clozapine increases the need for additional psychotropics and risks associated with antipsychotic polypharmacy, and can unnecessarily prolong the patient�s suffering and the length of hospitalization. A relationship between a faster titration and a higher incidence of clozapine-induced dangerous adverse effects has not been clearly demonstrated by clinical trials. Therapeutic drug monitoring is of great importance for drugs with a high inter-individual variability in serum concentration, a narrow therapeutic range or serious toxic side effects.

show abstract

The relevance of motivation in schizophrenia

Cited by 2 publications

References 0 publications

Dietary Behaviors and Metabolic Syndrome in Schizophrenia Patients

Dietary Behaviors and Metabolic Syndrome in Schizophrenia Patients

Clozapine Efficacy, Type of Titration and Therapeutic Drug Monitoring Using Chemical Methods for Serum Level Assessment

Contact Info

Product

Resources

About